Analyst Price Targets — VTVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 12:23 pm | Kambiz Yazdi | BTIG | $49.00 | $33.86 | TheFly | vTv Therapeutics price target raised to $49 from $40 at BTIG |
| January 22, 2026 9:07 pm | — | Roth Capital | $58.00 | $33.54 | TheFly | vTv Therapeutics initiated with a Buy at Roth Capital |
| December 19, 2025 1:18 pm | — | H.C. Wainwright | $47.00 | $36.30 | TheFly | vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright |
Latest News for VTVT
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 4,000 stock options to purchase shares of common stock to a non-executive…
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VTVT.
U.S. House Trading
No House trades found for VTVT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.